Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Bras Pneumol ; 48(5): e20220146, 2022.
Artigo em Inglês, Português | MEDLINE | ID: mdl-36350952

RESUMO

OBJECTIVE: To describe the performance of a pulmonologist-led lung cancer screening program using low dose CT (LDCT) in a cohort of outpatients with stable respiratory diseases in the Brazilian public health care system. METHODS: This was a retrospective analysis of the first two rounds of lung cancer screening of patients enrolled in the program. Inclusion criteria were being between 55 and 80 years of age, being a current or former smoker (smoking cessation ≤ 15 years), and having a smoking history ≥ 30 pack-years. LDCT results were interpreted in accordance with the Lung CT Screening Reporting and Data System, and those with a score of 3 or 4 were considered positive screening. Incidental pleuropulmonary findings were sought in all reports. RESULTS: LDCTs were requested for 791 patients during the study period, and 712 patients (90%) met the screening criteria. The mean patient age was 63 years, and most participants were current smokers (56%) with emphysema (78.5%) and other pleuropulmonary findings on CT (64%). Screening was positive in 14.0% and 5.6% of the cases in the first and second screening rounds, respectively. Lung cancer was detected in 1.5% of the patients in both first and second rounds (positive predictive value: 11.0% and 26.6%, respectively). The rate of early-stage (TNM I or II) screen-detected non-small cell carcinoma was 64.3%. Of the patients with positive screening, 19% were lost to follow-up before investigation was complete. CONCLUSIONS: The results of this screening program suggest its adequate performance in a cohort of patients with significant respiratory morbidity. The loss to follow-up rate highlights the need for constant monitoring and interventions to ensure adherence.


Assuntos
Neoplasias Pulmonares , Humanos , Adolescente , Pessoa de Meia-Idade , Neoplasias Pulmonares/patologia , Detecção Precoce de Câncer/métodos , Brasil/epidemiologia , Estudos Retrospectivos , Fumar/efeitos adversos , Fumar/epidemiologia , Tomografia Computadorizada por Raios X/métodos , Programas de Rastreamento , Hospitais Públicos
2.
J Bras Pneumol ; 48(6): e20220265, 2022.
Artigo em Inglês, Português | MEDLINE | ID: mdl-36449821

RESUMO

OBJECTIVE: There is still limited information on the clinical characteristics and outcomes of cystic fibrosis (CF) patients with COVID-19 in Brazil. The objective of this study was to describe the cumulative incidence of COVID-19 in CF patients, as well as their clinical characteristics and outcomes. METHODS: This was a prospective cohort study involving unvaccinated adult CF patients and conducted during the first year of the SARS-CoV-2 pandemic in the city of Porto Alegre, in southern Brazil. The clinical course of the disease was rated on the WHO Ordinal Scale for Clinical Improvement. The primary outcome was the number of incident cases of COVID-19. RESULTS: Between April 30, 2020 and April 29, 2021, 98 CF patients were included in the study. Seventeen patients were diagnosed with COVID-19. For the CF patients, the annual cumulative incidence of COVID-19 was 17.3%, similar to that for the general population, adjusted for age (18.5%). The most common symptoms at diagnosis of COVID-19 were cough (in 59%), dyspnea (in 53%), fatigue (in 53%), and fever (in 47%). Only 6 (35%) of the patients required hospitalization, and 3 (17.6%) required oxygen support. Only 1 patient required mechanical ventilation, having subsequently died. CONCLUSIONS: During the first year of the SARS-CoV-2 pandemic in southern Brazil, the cumulative incidence rate of COVID-19 was similar between CF patients and the general population. More than 50% of the CF patients with SARS-CoV-2 infection had a mild clinical presentation, without the need for hospital admission, and almost the entire sample recovered completely from the infection, the exception being 1 patient who had advanced lung disease and who died.


Assuntos
COVID-19 , Fibrose Cística , Adulto , Humanos , COVID-19/epidemiologia , SARS-CoV-2 , Pandemias , Fibrose Cística/complicações , Fibrose Cística/epidemiologia , Fibrose Cística/terapia , Brasil/epidemiologia , Estudos Prospectivos
3.
J. bras. pneumol ; 48(5): e20220146, 2022. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1405421

RESUMO

ABSTRACT Objective: To describe the performance of a pulmonologist-led lung cancer screening program using low dose CT (LDCT) in a cohort of outpatients with stable respiratory diseases in the Brazilian public health care system. Methods: This was a retrospective analysis of the first two rounds of lung cancer screening of patients enrolled in the program. Inclusion criteria were being between 55 and 80 years of age, being a current or former smoker (smoking cessation ≤ 15 years), and having a smoking history ≥ 30 pack-years. LDCT results were interpreted in accordance with the Lung CT Screening Reporting and Data System, and those with a score of 3 or 4 were considered positive screening. Incidental pleuropulmonary findings were sought in all reports. Results: LDCTs were requested for 791 patients during the study period, and 712 patients (90%) met the screening criteria. The mean patient age was 63 years, and most participants were current smokers (56%) with emphysema (78.5%) and other pleuropulmonary findings on CT (64%). Screening was positive in 14.0% and 5.6% of the cases in the first and second screening rounds, respectively. Lung cancer was detected in 1.5% of the patients in both first and second rounds (positive predictive value: 11.0% and 26.6%, respectively). The rate of early-stage (TNM I or II) screen-detected non-small cell carcinoma was 64.3%. Of the patients with positive screening, 19% were lost to follow-up before investigation was complete. Conclusions: The results of this screening program suggest its adequate performance in a cohort of patients with significant respiratory morbidity. The loss to follow-up rate highlights the need for constant monitoring and interventions to ensure adherence.


RESUMO Objetivo: Descrever o desempenho de um programa de rastreamento de câncer de pulmão conduzido por pneumologistas usando TC de baixa dose (TCBD) em uma coorte de pacientes ambulatoriais com doença respiratória estável no sistema público de saúde brasileiro. Métodos: Análise retrospectiva das duas primeiras rodadas de rastreamento de câncer de pulmão em pacientes inscritos no programa. Os critérios de inclusão foram ter idade entre 55 e 80 anos, ser fumante atual ou ex-tabagista (cessação do tabagismo ≤ 15 anos) e carga tabágica ≥ 30 anos-maço. Os resultados do TCBD foram interpretados de acordo com o Lung CT Screening Reporting and Data System, e aqueles com pontuação 3 ou 4 foram considerados exames positivos. Achados pleuropulmonares incidentais foram verificados em todos os relatórios. Resultados: TCBD foram solicitadas para 791 pacientes durante o período do estudo, e 712 pacientes (90%) preencheram os critérios de rastreamento. A média de idade dos pacientes foi de 63 anos, e a maioria dos participantes era fumante atual (56%) com enfisema (78,5%) e outros achados pleuropulmonares na TC (64%). O rastreamento foi positivo em 14,0% e 5,6% dos casos na primeira e segunda rodada, respectivamente. O câncer de pulmão foi detectado em 1,5% dos pacientes tanto na primeira quanto na segunda rodada (valor preditivo positivo: 11,0% e 26,6%, respectivamente). A taxa de carcinoma de células não pequenas detectado em estágio inicial (TNM I ou II) foi de 64,3%. Dos pacientes com rastreamento positivo, 19% foram perdidos no seguimento antes da conclusão da investigação. Conclusões: Os resultados deste programa de rastreamento sugerem um desempenho adequado em uma coorte de pacientes com morbidades respiratórias significativas. A taxa de perda de seguimento destaca a necessidade de monitoramento constante e intervenções para garantir a adesão.

4.
J. bras. pneumol ; 48(6): e20220265, 2022. tab, graf
Artigo em Inglês | LILACS-Express | LILACS | ID: biblio-1405438

RESUMO

ABSTRACT Objective: There is still limited information on the clinical characteristics and outcomes of cystic fibrosis (CF) patients with COVID-19 in Brazil. The objective of this study was to describe the cumulative incidence of COVID-19 in CF patients, as well as their clinical characteristics and outcomes. Methods: This was a prospective cohort study involving unvaccinated adult CF patients and conducted during the first year of the SARS-CoV-2 pandemic in the city of Porto Alegre, in southern Brazil. The clinical course of the disease was rated on the WHO Ordinal Scale for Clinical Improvement. The primary outcome was the number of incident cases of COVID-19. Results: Between April 30, 2020 and April 29, 2021, 98 CF patients were included in the study. Seventeen patients were diagnosed with COVID-19. For the CF patients, the annual cumulative incidence of COVID-19 was 17.3%, similar to that for the general population, adjusted for age (18.5%). The most common symptoms at diagnosis of COVID-19 were cough (in 59%), dyspnea (in 53%), fatigue (in 53%), and fever (in 47%). Only 6 (35%) of the patients required hospitalization, and 3 (17.6%) required oxygen support. Only 1 patient required mechanical ventilation, having subsequently died. Conclusions: During the first year of the SARS-CoV-2 pandemic in southern Brazil, the cumulative incidence rate of COVID-19 was similar between CF patients and the general population. More than 50% of the CF patients with SARS-CoV-2 infection had a mild clinical presentation, without the need for hospital admission, and almost the entire sample recovered completely from the infection, the exception being 1 patient who had advanced lung disease and who died.


RESUMO Objetivo: Ainda não há informações suficientes sobre as características clínicas e desfechos de pacientes com fibrose cística (FC) e COVID-19 no Brasil. O objetivo deste estudo foi descrever a incidência cumulativa de COVID-19 em pacientes com FC, bem como suas características clínicas e desfechos. Métodos: Estudo prospectivo de coorte com adultos com FC não vacinados, realizado na cidade de Porto Alegre, no sul do Brasil, durante o primeiro ano da pandemia de SARS-CoV-2. A evolução clínica da COVID-19 foi avaliada por meio da WHO Ordinal Scale for Clinical Improvement (escala ordinal de evolução clínica, elaborada pela OMS). O desfecho primário foi o número de casos incidentes de COVID-19. Resultados: Entre 30 de abril de 2020 e 29 de abril de 2021, 98 pacientes com FC foram incluídos no estudo. Dezessete pacientes receberam diagnóstico de COVID-19. Nos pacientes com FC, a incidência cumulativa anual de COVID-19 foi de 17,3%, semelhante à observada na população geral, ajustada pela idade (18,5%). Os sintomas mais comuns no momento do diagnóstico de COVID-19 foram tosse (em 59%), dispneia (em 53%), fadiga (em 53%) e febre (em 47%). Apenas 6 (35%) dos pacientes necessitaram de hospitalização, e 3 (17,6%) necessitaram de suporte de oxigênio. Apenas 1 paciente necessitou de ventilação mecânica e, posteriormente, morreu. Conclusões: Durante o primeiro ano da pandemia de SARS-CoV-2 no sul do Brasil, a taxa de incidência cumulativa de COVID-19 foi semelhante nos pacientes com FC e na população geral. Mais de 50% dos pacientes com FC e infecção por SARS-CoV-2 apresentaram manifestações clínicas leves, sem necessidade de internação hospitalar, e quase toda a amostra se recuperou completamente da infecção, à exceção de 1 paciente, que apresentava doença pulmonar avançada e morreu.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...